Stay updated on DS-8201a in HER2 NSCLC Clinical Trial
Sign up to get notified when there's something new on the DS-8201a in HER2 NSCLC Clinical Trial page.

Latest updates to the DS-8201a in HER2 NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a government-operating-status notice and a new version tag (v3.2.0); removed the old version tag (v3.1.0).SummaryDifference3%
- Check20 days agoChange DetectedPage version updated from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.1%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2 and Back to Top was removed; overall changes are minor and do not affect core content or user-facing information.SummaryDifference0.2%
- Check41 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check49 days agoChange DetectedThe webpage has undergone significant updates, including the addition of specific facility names and locations, as well as detailed references to studies involving Trastuzumab Deruxtecan. Notably, the previous mentions of Trastuzumab and certain location details have been removed.SummaryDifference8%
- Check63 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to DS-8201a in HER2 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DS-8201a in HER2 NSCLC Clinical Trial page.